Fibrolamellar carcinoma: Challenging the challenge
| Autor: | Rafik Filobbos, Melissa Frizziero, Mairéad G McNamara, Angela Lamarca, Steve Wardell, Alexander Jp Fulton, Richard A Hubner, Juan W. Valle |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Male Cancer Research medicine.medical_specialty Carcinoma Hepatocellular Malignancy Systemic therapy Limited access 03 medical and health sciences 0302 clinical medicine hemic and lymphatic diseases medicine Humans Intensive care medicine business.industry Liver Neoplasms medicine.disease Clinical trial 030104 developmental biology Oncology 030220 oncology & carcinogenesis Hepatocellular carcinoma Treatment Schedule Female business Fibrolamellar Carcinoma Epirubicin medicine.drug |
| Zdroj: | European journal of cancer (Oxford, England : 1990). 137 |
| ISSN: | 1879-0852 |
| Popis: | Fibrolamellar carcinoma (FLC) is a rare and poorly understood malignancy, which seems to be more prevalent in young patients compared with conventional hepatocellular carcinoma (HCC). Performing prospective clinical trials recruiting patients diagnosed with FLC has proven challenging with scarce data available guiding clinical management. The use of a number of chemotherapy compounds in these patients, including cisplatin, epirubicin, 5-fluorouracil (5-FU) and recombinant interferon α-2B (IFN-α-2B), has been reported in the literature, mainly in the form of case reports. The most promising systemic therapy tested so far is the combination of 5-FU infusion and 3-weekly IFN-α-2B, based on results from a phase II clinical trial. This article provides an overview of our own experience with this treatment schedule for patients with FLC, confirming its activity and treatment-derived benefit in the real world. Current challenges being faced by healthcare professionals treating patients with advanced FLC are discussed, especially the increasingly limited access to IFN-α-2B, which could compromise the access to an active therapy in the coming future, and the difficulties in the development of new treatment options for advanced FLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect